Mumbai-based Wellthy Therapeutics, a digital therapeutics company that uses artificial intelligence (AI) and patient centric design to improve patient outcomes for all healthcare stakeholders in diabetes care, announced results from a pilot designed to evaluate the feasibility and scalability of an artificial intelligence led lifestyle intervention to improve self-management of people living with type 2 diabetes as a supporting tool to existing care in India. The results were featured via an oral presentation at the American Diabetes Association (ADA) 77th Scientific Sessions, taking place at the San Diego Convention Centre in San Diego, California. The pilot results suggest that continuity of care between physician appointments for people with type 2 diabetes can be achieved with positive outcomes in a clinically significant, scalable and affordable way through this program. Participants that completed the pilot on average dropped their average blood sugar levels (HbA1c) by 0.59%. Amongst the participants that completed and dropped their HbA1c, the average drop observed was even higher at 1.04%.

New Delhi [India], Dec 21 (ANI-BusinessWireIndia): The Research Society for The Study of Diabetic in India (RSSDI) has partnered with Wellthy Therapeutics, a digital therapeutics company focused on improving diabetes care and outcomes through Artificial Intelligence. Wellthy Diabetes is an artificial intelligence powered diabetes health coach for patients and a virtual clinical assistant for doctors. This is a first of its kind RSSDI endorsement for an application that can be prescribed by doctors to patients. The partnership was announced at the recently concluded annual RSSDI conference held in Hyderabad. Over the last 20 years, billions of dollars have been spent on pharma and med device research.